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ReportsRetinopathy Associated with
Biallelic Mutations in PYGM
(McArdle Disease)Identiﬁcation of ocular associations with systemic diseases can aid
diagnosis and phenotyping and can yield pathophysiologic
insights. McArdle disease (glycogen storage disease type V) is a
rare metabolic myopathy (estimated prevalence, 1/100 000)
resulting from biallelic mutations in the PYGM gene, encoding
muscle glycogen phosphorylase (reviewed by Lucia et al1).
Patients experience exercise intolerance and risk acute
rhabdomyolysis, although life expectancy is rarely affected. A
case report from 1988 described pattern dystrophy of the retinal
pigment epithelium (RPE) in an affected patient.2 Two further
cases have been reported.3,4 With only 3 cases, chance associa-
tion is possible; the 2 entities may be unrelated.
Pattern dystrophies can be associated with mutations in a
number of genes, most frequently PRPH2. We describe here a
similar macular appearance in 4 further, unrelated patients with
McArdle disease, including ﬁndings from multimodal retinal im-
aging and electrophysiologic examination. Genetic screening was
performed, both to conﬁrm PYGM mutations and to check for
mutations in a number of known genes implicated in macular or
pattern dystrophies. The latter screening showed negative results,
suggesting that the 2 entities (retinopathy and McArdle disease) are
indeed related. This study had research ethics committee approval.
Patient 1, a 64-year-old white man, was referred because of
longstanding reduction in right eye vision and an unusual macular
appearance. He reported exercise intolerance since childhood and
had been diagnosed with McArdle disease after muscle biopsy.
Unaided Snellen visual acuity was 20/80 in the right eye (20/60 with
pinhole) and 20/20 in the left eye. Over the next 10 years, visual
acuity deteriorated in the right eye to counting ﬁngers but remained
stable in the left eye. Patient 2, a 63-year-old South Asian man, was
referred for reduction in left eye vision over the previous few years.
McArdle disease had been diagnosed in late adulthood after muscle
biopsy. Visual acuity was 20/17 in the right eye and 20/60 in the left
eye; 4 years later, visual acuity was 20/20 and 20/80, respectively.
Patient 3, a 56-year-old white man, was noted previously to have
an abnormal retinal appearance by his optometrist. He had been
diagnosed with McArdle disease (molecularly conﬁrmed) 2 years
before review in our service. He was visually asymptomatic; visual
acuitywas 20/17 in each eye. Patient 4, a 68-year-oldwhiteman, was
referred to his local hospital eye service after his optometrist noted an
abnormal retinal appearance. He had no visual problems other than
refractive error. He had been diagnosed by his local ophthalmology
service, based on the macular appearance, with Stargardt disease.
McArdle disease had been diagnosed after muscle biopsy in his 30s,
although he reported fatigue since childhood. Visual acuity was
20/40 in the right eye and 20/30 in the left eye.
Figure 1 depicts the appearance of the fundus on color
photography and autoﬂuorescence, the latter showing distinctive
reticular areas of stippled hyperautoﬂuorescence. Spectral-domain
OCT (Fig S1, available at www.aaojournal.org) conﬁrmed320abnormalities at the level of the RPE, outer retina, or both. Ultra-
wideﬁeld autoﬂuorescence imaging showed abnormalities in the
far peripheral retina also, particularly nasally (Fig S2, available at
www.aaojournal.org).
Patients 1, 2, and 4 underwent electroretinography recording
according to international standards. All demonstrated normal full-
ﬁeld electroretinography results; pattern electroretinograms were
undetectable in patient 1 and within normal limits in patients 2 and
4. Patients 1 and 2 also underwent electro-oculography, which
showed a normal light rise.
Patients 1 and 2 underwent Sanger sequencing of all coding
exons and exon-intron boundaries of PRPH2, thought to be the
most likely genetic cause of such a fundus appearance (Manchester
Centre for Genomic Medicine, Manchester, United Kingdom). No
pathogenic variants were found. All patients underwent screening
for disease-causing mutations in a number of additional genes
implicated in macular or pattern dystrophies: ABCA4, BEST1,
CDH3, EFEMP1, ELOVL4, IMPG1, IMPG2, PROM1, PRPH2,
TIMP3; Molecular Vision Laboratory, Hillsboro, Oregon). For
patients 2, 3, and 4, the panel also included DRAM2, RP1L1, and
TTLL5. Results were negative.
Screening of PYGM (Shefﬁeld Diagnostic Genetics Service,
Shefﬁeld, United Kingdom) molecularly conﬁrmed McArdle dis-
ease in all patients. Patient 1 was homozygous for the frequently
reported nonsense mutation p.(Arg50*). Patient 2 harbored the
novel homozygous stop mutation p.(Gln176*). Patients 3 and 4
were compound heterozygotes: patient 3, p.(Arg50*) and
p.(Gly205Ser); patient 4, p.(Arg94Trp) and p.(Gly695Arg).
In all patients, diagnosis of McArdle disease preceded detection
of retinal abnormalities (apart from patient 3). Patients 1 and 2
were referred to the ophthalmology service because of visual
symptoms; patients 3 and 4 were visually asymptomatic, but an
optometrist detected an abnormal fundal appearance. Genetic
testing for macular or pattern dystrophy genes was initiated by our
service, and genetic conﬁrmation of McArdle disease also was
obtained after review in our service (except in patient 3).
This article reports multimodal imaging ﬁndings of a distinctive
retinopathy in4unrelated patientswithMcArdle disease, similar to the
previous case reports. We also report results of retinal electrophysi-
ologic analysis: despite far peripheral abnormalities on ultrawide-ﬁeld
imaging, there was no deﬁnite electrophysiologic evidence of gener-
alized retinal, or generalized RPE, dysfunction (full-ﬁeld electroreti-
nography and electro-oculography light rise results were normal).
Screening results for mutations in a number of macular dys-
trophy genes were negative. In particular, the ﬁndings could not be
attributed to mutations in PRPH2, which would have been most
likely to result in a similar retinal phenotype. Patient 4 had been
diagnosed previously with Stargardt disease, but genetic testing
yielded no mutations in ABCA4. The results of this study are of
clinical signiﬁcance because they support the association of this
retinopathy with McArdle disease and can reduce the likelihood of
misdiagnosis; this is increasingly important because particular
genetic causes of retinopathy (including ABCA4) are subject to a
number of novel treatment trials.
Figure 1. Retinal appearance on color imaging (left panels) and fundus autoﬂuorescence (FAF) imaging (right panels). A, Color fundus images from patient
1. B, Short-wavelength (488-nm) posterior pole (55) FAF images from patient 1. C, D, Corresponding images from patient 2. E, F, Corresponding images
from patient 3. G, H, Pseudocolor image and 488-nm FAF image from patient 4. In all cases, yellow reticular lesions are visible on color imaging, with
atrophy in patient 1 and small areas of pigmentary change in patients 2, 3, and 4. Fundus autoﬂuorescence (FAF) shows reticular hyperautoﬂuorescence
(likely to result from loss of photoreceptor outer segments, accumulation of ﬂuorophore in the retinal pigment epithelium [RPE], or both) in all cases, with
additional dark areas indicating RPE atrophy in patient 1.
ReportsWhymight muscle glycogen phosphorylase deﬁciency affect the
retina? The enzyme catalyses conversion of glycogen to glucose-1-
phosphate in skeletal muscle. Liver, muscle, and brain have
different isoforms of the enzyme. In human RPE, glycogen is pre-
sent, and bothmuscle and brain isoenzymes have been demonstrated.
Intracellular glycogen is likely to act as a buffer5 in glucose delivery
from choroid to photoreceptors via the RPE. It is possible that
deﬁciency of a glycogen phosphorylase isoenzyme may disturb
this process, leading to degeneration. This is one hypothesis; other
mechanisms are possible, and further work is needed.
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Res. 2006;83:235e246.Telemetric Intraocular Pressure
Monitoring after Boston
Keratoprosthesis SurgeryThe use of the Boston keratoprosthesis Type I (BI-KPro) implan-
tation to restore vision in corneal blindness has considerably
increased worldwide.1,2 Patients with severe corneal opaciﬁcation
without realistic prognosis for success of a corneal transplant can
beneﬁt from this treatment. Secondary glaucoma has been322identiﬁed as one of the 2 most common complications after BI-
KPro surgery occurring on average in almost every third patient
and being the most frequent reason for long-term vision loss.3
Because of the physical properties of the BI-KPro, measure-
ment of intraocular pressure (IOP) by established methods is not
feasible after surgery. Therefore, IOP can be estimated only by
ﬁnger palpation. This technique is prone to high variability,
resulting in an unmet clinical need for new concepts to reliably
monitor IOP after keratoprosthesis surgery.
Continuous IOP measurement with an implantable sensor was
described decades ago. Despite different approaches, no system has
reached clinical applicability until now, mainly because of tech-
nical difﬁculties.
The telemetric ARGOS-IO IOP sensor (Implandata Ophthalmic
Products GmbH, Hanover, Germany) combines an implantable IOP
sensor ring consistingof amicroelectromechanical systemapplicatione
speciﬁc integrated circuit with a handheld reading device to measure
IOP (Fig 1). An electromagnetic inductive connection between the coil
of the sensor and the activated reader powers the circuit, initiating a
pressure reading and enabling telemetric data transfer.
We report the 1-year results of a prospective, open-label,
multicenter, single-arm clinical trial aimed to assess the safety,
tolerability, and performance of the ARGOS-IO telemetric IOP
sensor implanted in eyes undergoing BI-KPro surgery.
This clinical trial was conducted in full accordance with the Decla-
ration of Helsinki (ICH-GCP, ISO14155:2011). All patients provided
written informed consent before enrollment. (ClinicalTrials.gov
identiﬁer: NCT02945176).
A total of 13 patients with an indication for BI-KPro implan-
tation were successfully screened and initially enrolled, 12 of
whom successfully received the implant (Table S1, available at
www.aaojournal.org). The surgical approach consisted of the
typical open sky approach for BI-KPro implantation. Dependent
on adequate capsular support, the sensor was placed in the ciliary
sulcus with or without additional suture ﬁxation to the sclera. The
pressure sensor was calibrated using direct intracameral manom-
etry in the anterior chamber to measure current IOP as reference.4
To assess safety of the implant, the study analyzed all serious
adverse events during the ﬁrst 12 months after implantation, as
well as adverse events and severe adverse device events occurring
in enrolled patients.
The primary objective to evaluate the performance of the study
device was the comparison of telemetric IOP measurement to
invasive IOP measurement using intracameral manometry.
Eight of 12 enrolled patients completed the study with the
sensor implanted in the eye. One patient voluntary withdrew from
the study with the sensor left in place. In 3 patients, the sensor was
explanted, either after dislocation in a patient with aniridia (n ¼ 1)
or after necessity for multiple additional ocular surgeries (n ¼ 2).
In these 2 cases, the sensor was removed to avoid potential addi-
tional complications, not because the sensor device caused or was
thought to cause the surgical revision.
Of 168 adverse events, 16 adverse events in 4 patients were rated
as possibly related to the medical device by the investigators. Those
potential (severe) adverse device events were anterior chamber cells,
cystoidmacular edema, hypotony, iris adhesion, pigment dispersion,
vitritis, increased IOP, and formation of a retroprosthetic membrane
(Table S2, available at www.aaojournal.org).
Surgical intracameral manometry was performed in a total of 24
visits in 9 patients. The study protocol entailedmanometry in 4 visits in
